Patents Issued in September 30, 2014
-
Patent number: 8846697Abstract: The present invention provides purine analog compounds, as well as compositions and methods of using them, for example, to prevent or treat various diseases and disorders in human and non-human animals.Type: GrantFiled: April 23, 2007Date of Patent: September 30, 2014Assignee: The Regents of the University of CaliforniaInventors: Dennis A. Carson, Howard B. Cottam, Guangyi Jin, Christina C. N. Wu, Suzanne Grimshaw
-
Patent number: 8846698Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.Type: GrantFiled: April 4, 2012Date of Patent: September 30, 2014Assignee: Pfizer LimitedInventors: Mark David Andrews, Sharanjeet Kaur Bagal, Karl Richard Gibson, Kiyoyuki Omoto, Thomas Ryckmans, Sarah Elizabeth Skerratt, Paul Anthony Stupple
-
Patent number: 8846699Abstract: The present invention relates to a novel quinazoline derivative compound having the formula (1) as follows: with the constituents defined in claim 1, and a pharmaceutically acceptable salt thereof as a multiplex inhibitor, a method for the preparation thereof, and a pharmaceutical composition and a therapeutic composition comprising same as an active ingredient. The inventive quinazoline derivative as a multiplex inhibitor can selectively and effectively inhibit diseases caused by the overactivity of a tyrosine kinase.Type: GrantFiled: November 8, 2006Date of Patent: September 30, 2014Assignee: Hanmi Pharm. Co., Ltd.Inventors: Young-Gil Ahn, Jong Woo Kim, Keuk Chan Bang, Bum Woo Park, Se Young Kim, Kyungik Lee, Kyuhang Lee, Myoung-Sil Ko, Han Kyong Kim, Young Hoon Kim, Maeng Sup Kim, Gwan Sun Lee
-
Patent number: 8846700Abstract: Disclosed are compounds of the following formula and their pharmaceutically-acceptable salts, which have an effect of glucokinase activation and are useful in the field of medicines for treatment for diabetes, obesity, etc. (wherein ring A represents a pyrazolyl group optionally having a lower alkyl group, etc.; ring B represents a heteroaryl group; R represents a lower alkyl group, etc.; R1 represents a group of a formula: (wherein R11 and R12 each independently represent a hydrogen atom, etc.; m indicates an integer of from 2 to 6), etc.; R2 represents a lower alkyl group, etc.; r indicates an integer of from 0 to 3; k indicates an integer of from 0 to 4).Type: GrantFiled: September 9, 2013Date of Patent: September 30, 2014Assignee: MSD K.K.Inventors: Tomoharu Iino, Akio Ohno, Norikazu Otake, Takuya Suga, Masanori Asai
-
Patent number: 8846701Abstract: The present invention relates to pyrazolo-quinazolines, characterized by an ortho-substituted-arylamino, heterocyclylamino- or C3-C7 cycloalkylamino residue at 8 position and an aryl, heterocyclyl or C3-C7 cycloalkyl as substituent of a carboxamide at 3 position of the molecule framework. The compounds of this invention modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular MPS1/TTK. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.Type: GrantFiled: June 17, 2009Date of Patent: September 30, 2014Assignee: Nerviano Medical Sciences S.R.L.Inventors: Marina Caldarelli, Mauro Angiolini, Riccardo Colombo, Teresa Disingrini, Stefano Nuvoloni, Helena Posteri, Matteo Salsa, Marco Silvagni
-
Patent number: 8846702Abstract: The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.Type: GrantFiled: August 26, 2010Date of Patent: September 30, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Ronald K. Chang, Thomas J. Greshock
-
Patent number: 8846703Abstract: To provide a crystal of a tricyclic pyrazolopyrimidine compound inhibiting the effect of HSP90. The present invention provides a crystal of 2-{4-amino-2-[(3-chloro-4-methoxy-5-methylpyridin-2-yl)methyl]-2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo[cd]azulen-8-yl}-N-methylacetamide which inhibits the ATPase activity of HSP90 and which has antitumor activity, a medicament comprising the same, an anticancer agent comprising the same, and the like.Type: GrantFiled: February 21, 2013Date of Patent: September 30, 2014Assignee: Daiichi Sankyo Company, LimitedInventors: Yasusi Ueda, Nobuyuki Suzuki, Hitoshi Ohki
-
Patent number: 8846704Abstract: The present invention relates to thiopyrimidine-based compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2 or JAK3 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases and vascular diseases.Type: GrantFiled: January 31, 2008Date of Patent: September 30, 2014Assignee: YM Biosciences Austraila Pty LtdInventors: David Gerard Bourke, Xianyong Bu, Christopher John Burns, Anthony Nicholas Cuzzupe, John Thomas Feutrill, Tracy Leah Nero, Beata Maria Blannin, Jun Zeng, Shaun Patrick Gaynor
-
Patent number: 8846705Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.Type: GrantFiled: December 8, 2010Date of Patent: September 30, 2014Assignee: Roche Palo Alto LLCInventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Ronald Charles Hawley, Alam Jahangir, Clara Jeou Jen Lin, Daniel Warren Parish
-
Patent number: 8846706Abstract: Crystalline forms of imatinib mesylate (F, G, H, I and K) and their respective characterization are disclosed.Type: GrantFiled: July 15, 2011Date of Patent: September 30, 2014Assignee: Novartis AGInventor: Michael Mutz
-
Patent number: 8846707Abstract: In one aspect, the invention relates to substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs, derivatives thereof, and related compounds, which are useful as inhibitors of STAT protein activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders of uncontrolled cellular proliferation associated with a STAT protein activity dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: August 2, 2011Date of Patent: September 30, 2014Assignees: Univeristy of Central Florida Research Foundation, Inc., The Governing Council of the University of TorontoInventors: James Turkson, Patrick Gunning
-
Patent number: 8846708Abstract: The present invention relates to a salt of a pyrimidin derivative of the acid (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamide)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic, to a method for preparing same and to the use thereof in formulating pharmaceutical formulations.Type: GrantFiled: October 4, 2011Date of Patent: September 30, 2014Assignee: Laboratorios Senosiain S.A. de C.V.Inventors: Juan Pablo Senosiain Peláez, Héctor Senosiain Arroyo, Manuel Francisco Lara Ochoa
-
Patent number: 8846709Abstract: Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.Type: GrantFiled: April 19, 2012Date of Patent: September 30, 2014Assignee: GlaxoSmithKline LLCInventors: Emmanuel Hubert Demont, Katherine Louise Jones, Robert J. Watson
-
Patent number: 8846710Abstract: A method of preferentially inducing IFN-? biosynthesis in an animal comprising administering certain imidazo[4,5-c] ring compounds with a hydroxymethyl or hydroxyethyl substituent at the 2-position or pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of using these compounds a immunomodulators for treatment of diseases including viral and neoplastic diseases comprising preferentially inducing IFN-? biosynthesis in an animal are disclosed.Type: GrantFiled: February 22, 2006Date of Patent: September 30, 2014Assignee: 3M Innovative Properties CompanyInventors: Tushar A. Kshirsagar, Bryon A. Merrill, Scott E. Langer, Kyle J. Lindstrom, Sarah C. Slania, Gregory J. Marszalek, Joshua R. Wurst, Karl J. Manske, Shri Niwas, Gregory D. Lundquist, Jr., Philip D. Heppner, George W. Griesgraber, Michael E. Danielson
-
Patent number: 8846711Abstract: The invention relates to novel heterocyclic acrylamide compounds (I), to the preparation of the compounds and intermediates used therein, to the use of the compounds as antibacterial medicaments and pharmaceutical compositions containing the compounds.Type: GrantFiled: November 17, 2010Date of Patent: September 30, 2014Assignee: Fab Pharma S.A.S.Inventors: Vincent Gerusz, Sonia Escaich, Mayalen Oxoby, Alexis Denis
-
Patent number: 8846712Abstract: The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I, in which R1, R2, R3, R4 and R5 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.Type: GrantFiled: September 12, 2011Date of Patent: September 30, 2014Assignee: SanofiInventors: Matthias Loehn, Maria Mendez-Perez, Stefania Pfeiffer-Marek, Aimo Kannt, Guillaume Begis, Olivier Duclos, Federic Jeannot
-
Patent number: 8846713Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia or so on represented by the formula (I):Type: GrantFiled: June 22, 2011Date of Patent: September 30, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Takahiko Taniguchi, Masato Yoshikawa, Kasei Miura, Tomoaki Hasui, Eiji Honda, Keisuke Imamura, Makoto Kamata
-
Patent number: 8846714Abstract: Provided herein are compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers:Type: GrantFiled: July 10, 2013Date of Patent: September 30, 2014Assignee: Samumed, LLCInventors: John Hood, Sunil Kumar KC, David Mark Wallace
-
Patent number: 8846715Abstract: The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems.Type: GrantFiled: July 22, 2013Date of Patent: September 30, 2014Assignee: Targacept, Inc.Inventors: Merouane Bencherif, Lisa Benson, Gary Maurice Dull, Nikolai Federov, Gregory J. Gatto, Kristen G. Jordan, Anatoly A. Mazurov, Lan Miao, Julio A. Munoz, Inigo Pfeiffer, Sondra Pfeiffer, Teresa Phillips
-
Patent number: 8846717Abstract: Insect controlling compositions including an N-substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximine compound exhibiting increased stability, along with methods for preparing same, are disclosed.Type: GrantFiled: March 15, 2013Date of Patent: September 30, 2014Assignee: Dow AgroSciences, LLC.Inventors: Kuide Qin, Raymond E. Boucher, Jr.
-
Patent number: 8846718Abstract: The present invention relates to a substantially crystalline and free solid state form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Form I), pharmaceutical compositions thereof, and methods of treatment therewith.Type: GrantFiled: July 2, 2013Date of Patent: September 30, 2014Assignee: Vertex Pharmaceuticals IncorporatedInventors: Ali Keshavarz-Shokri, Beili Zhang, Mariusz Krawiec
-
Patent number: 8846719Abstract: The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R1 to R6 are as described herein. The compounds are active on the GABA A ?5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.Type: GrantFiled: June 12, 2013Date of Patent: September 30, 2014Assignee: Roche Palo Alto LLCInventors: Bernd Buettelmann, Roland Jakob-Roetne, Henner Knust, Matthew C. Lucas, Andrew Thomas
-
Patent number: 8846720Abstract: The present invention provides a composition having an excellent controlling activity on a pest. The composition comprising a compound represented by Formula (1) and one or more diamide compound(s) selected from Group (A) shows an excellent controlling activity on a pest.Type: GrantFiled: October 13, 2011Date of Patent: September 30, 2014Assignee: Sumitomo Chemical Company, LimitedInventors: So Kiguchi, Soichi Tanaka
-
Patent number: 8846721Abstract: Novel small molecule compounds for reduction of A? 42 production and for treatment of Alzheimer?s Disease and other neurodegenerative disorders, methods of making them and pharmaceutical compositions containing them are described.Type: GrantFiled: January 22, 2011Date of Patent: September 30, 2014Assignee: Kareus Therapeutics SAInventors: Venkateswarlu Akella, Uday Saxena, Anji Reddy Kallam
-
Patent number: 8846722Abstract: Methods and formulations for treating animal ectoparasites, effective against parasites such as fleas and ticks are provided. The methods comprise topically co-administering a non-mobile insect growth regulator and a mobile insect growth regulator to the animal. Parasiticidal formulations for treating animal ectoparasites are also provided, which can be safe to use and avoid the many common deleterious side effects of conventional topical formulations. The topical formulations comprise a combination of two insect growth regulators, a non-mobile insect growth regulator and a mobile insect growth regulator. The topical formulation can be packaged with the two insect growth regulators together or packaged to prevent mixing of the two insect growth regulators prior to administering the topical insecticide formulation to the animal.Type: GrantFiled: June 22, 2012Date of Patent: September 30, 2014Assignee: The Hartz Mountain CorporationInventors: William Ecker, Lance Hemsarth
-
Patent number: 8846723Abstract: Esters of O-substituted hydroxy carboxylic acids are provided having Formula 1, or 2, or both Formulas 1 and 2: wherein R and R1 are independently selected from the group consisting of substituted and unsubstituted, branched- and straight-chain, saturated, unsaturated, and polyunsaturated C1-C22 alkyl, substituted and unsubstituted C3-C8 cycloalkyl, substituted and unsubstituted C6-C20 carbocyclic aryl, and substituted and unsubstituted C4-C20 heterocyclic; wherein the heteroatoms are selected from sulfur, nitrogen, and oxygen; and wherein n is 1-6. Process of producing esters of O-substituted hydroxy carboxylic acids are also provided.Type: GrantFiled: December 22, 2010Date of Patent: September 30, 2014Assignees: Eastman Chemical Company, Chanel Parfums BeauteInventors: Liu Deng, Neil Warren Boaz, Sabine Delaire
-
Patent number: 8846724Abstract: Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively.Type: GrantFiled: July 27, 2011Date of Patent: September 30, 2014Assignees: President and Fellows of Harvard College, The General Hospital CorporationInventors: David A. Sinclair, Maria Alexander-Bridges
-
Patent number: 8846725Abstract: Compositions and methods for treating disordered tissues, such as caused by pathogens and/or by toxins. The treatment compositions include an anti-infective active agent, a liquid carrier, and benzocaine in an amount so that the treatment composition penetrates more quickly into disordered tissue compared to the treatment composition in the absence of the benzocaine. In addition, the benzocaine can increase residence time of the anti-infective active in the treatment area. The preferred anti-infective active agent can be an organohalide, such as a quaternary ammonium halide compound, an example of which is benzalkonium chloride. The treatment compositions and methods may employ the use of an applicator adapted for use in promoting penetration of the treatment composition and/or agitation of the disordered tissue to further enhance penetration.Type: GrantFiled: January 24, 2011Date of Patent: September 30, 2014Assignee: Quadex Pharmaceuticals, LLCInventors: B. Ron Johnson, James P. McCarthy
-
Patent number: 8846726Abstract: The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.Type: GrantFiled: January 4, 2013Date of Patent: September 30, 2014Assignee: Incyte CorporationInventors: Andrew P. Combs, Eddy W. Yue
-
Patent number: 8846727Abstract: A new class of haloalkyl heteroaryl benzamides is described. These compounds show strong activity against hepatitis viruses.Type: GrantFiled: May 11, 2010Date of Patent: September 30, 2014Assignee: Romark Laboratories, L.C.Inventors: Jean-Francois Rossignol, J. Edward Semple
-
Patent number: 8846728Abstract: The present invention relates to novel oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: GrantFiled: June 26, 2013Date of Patent: September 30, 2014Assignee: Allergan, Inc.Inventors: Wenkui K. Fang, Evelyn G. Corpuz, Wha-Bin Im, Ken Chow, Liming Wang
-
Patent number: 8846729Abstract: The present invention relates to 2-thio-1,3,4-oxadiazoles azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: GrantFiled: November 7, 2013Date of Patent: September 30, 2014Assignee: Allergan, Inc.Inventors: Janet A. Takeuchi, Ling Li, Wha-Bin Im, Ken Chow
-
Patent number: 8846730Abstract: The present application relates to cannabinoid receptor ligands of formula (I) wherein X1, A1, Rx, R2, R3, R4, and z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions.Type: GrantFiled: September 4, 2009Date of Patent: September 30, 2014Assignee: AbbVie Inc.Inventors: William A. Carroll, Michael J. Dart, Jennifer M. Frost, Teodozyj Kolasa, Tongmei Li, Bo Liu, Arturo Perez-Medrano, Meena Patel, Xueqing Wang, Sridhar Peddi
-
Patent number: 8846731Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogs, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.Type: GrantFiled: October 6, 2011Date of Patent: September 30, 2014Assignee: FerroKin Biosciences, Inc.Inventors: Amy E. Tapper, Hugh Y. Rienhoff, Jr., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
-
Patent number: 8846732Abstract: Biogenic sulfide production is synergistically inhibited by treating sulfate-reducing bacteria (SRB) with a biocide and a metabolic inhibitor. The biocide directly kills a first portion of the SRB. The metabolic inhibitor inhibits sulfate-reducing growth of a second portion of the SRB without directly killing the second portion of the SRB. The treatment of SRB with both a biocide and a metabolic inhibitor provides effective biogenic sulfide inhibition at significantly lower concentrations than would be required if the biocide or metabolic inhibitor was used alone.Type: GrantFiled: October 6, 2010Date of Patent: September 30, 2014Assignees: ConocoPhillips Company, University Technologies International, Inc.Inventors: Gary E. Jenneman, Anne Greene, Gerrit Voordouw
-
Patent number: 8846733Abstract: The invention relates to oxazolyl-methylether derivatives of formula (I), wherein R1, R2, R3, R4 and R5 are as defined in the description, their preparation and their use as pharmaceutically active compounds.Type: GrantFiled: December 6, 2011Date of Patent: September 30, 2014Assignee: Actelion Pharmaceuticals Ltd.Inventors: Daniel Bur, Olivier Corminboeuf, Sylvaine Cren, Corinna Grisostomi, Xavier Leroy, Sylvia Richard-Bildstein
-
Patent number: 8846734Abstract: Diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders, and related pharmaceutical compositions are provided.Type: GrantFiled: November 25, 2013Date of Patent: September 30, 2014Assignee: Joyant Pharmaceuticals, Inc.Inventors: Qi Wei, Ming Zhou, Xiaoming Xu, Charles Caldwell, Susan Harran, Lai Wang
-
Patent number: 8846735Abstract: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infection.Type: GrantFiled: October 11, 2013Date of Patent: September 30, 2014Assignee: Microdose Therapeutx, Inc.Inventors: Theodore J. Nitz, Janet A. Gaboury, Christopher J. Burns, Sylvie Laguerre, Daniel C. Pevear, Thomas A. Lessen, David J. Rys
-
Patent number: 8846736Abstract: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.Type: GrantFiled: March 11, 2014Date of Patent: September 30, 2014Assignee: N30 Pharmaceuticals, Inc.Inventors: Jan Wasley, Gary J. Rosenthal, Xicheng Sun, Sarah Strong, Jian Qiu
-
Patent number: 8846737Abstract: There is provided a compound of formula I wherein Z is selected from N and CR22, wherein R22 is H or a bond with D; wherein D is selected from a bond, C?O, and linear or branched hydrocarbon groups having a carbon chain of from 1 to 6 carbon atoms, wherein the carbon chain optionally contains an oxy group (?O), an ether (—O—) or thioether (—S—) link, wherein R1 is selected from: triazolyl, imidazolyl, pyrimidinyl radical wherein each of R2 to R6 is independently selected from —H, NO2, halo, —CN, —N[(C?O)0-1R12][(C?O)0-1R13] and —(CH2)0-1R14, or two adjacent groups of R2 to R6, together with the carbon atoms to which they are attached, form a ring, wherein at least one of R2 to R6 is —CN, wherein (i) at least one of R2 to R6 is —(CH2)0-1R14, or (ii) at least one of R2 to R6 is —N[(C?O)0-1R12][(C?O)0-1R13], or (iii) at least two adjacent groups of R2 to R6 together with the carbon atoms to which they are attached, form a ring, or (iv) at least one of R2 to R6 is —(CH2)0-1—O—R?14, wherein R12 and R13Type: GrantFiled: August 23, 2010Date of Patent: September 30, 2014Assignee: Sterix LimitedInventors: Lok Wai Lawrence Woo, Christian Bubert, Paul Michael Wood, Aurélien Putey, Atul Purohit, Barry Victor Lloyd Potter
-
Patent number: 8846738Abstract: The novel active compound combinations comprising 2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-[1,2,4]-triazole-3-thione of the formula and the active compound of groups (1) to (24) listed in the description have very good fungicidal properties.Type: GrantFiled: January 15, 2013Date of Patent: September 30, 2014Assignee: Bayer Intellectual Property GmbHInventors: Stefan Dutzmann, Klaus Stenzel, Manfred Jautelat
-
Patent number: 8846739Abstract: TGR5 agonists of structural formula VIII(Q), wherein X, R1, R2, and R5 are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.Type: GrantFiled: August 11, 2010Date of Patent: September 30, 2014Assignee: Exelixis Patent Company LLCInventors: Venkataiah Bollu, Brant Clayton Boren, Jackaline Dalgard Julien, Brenton T. Flatt, Nadia Haq, Sarah Hudson, Raju Mohan, Michael Morrissey, Benjamin Pratt
-
Patent number: 8846740Abstract: An occlusive dressing made with an elastomeric gel and one or more active agents is described. The elastomeric gel contains a plasticizing oil phase and a block copolymer agent. Methods of preventing, treating, curing or mitigating an infectious disease and methods of making the dressings are also disclosed.Type: GrantFiled: January 4, 2012Date of Patent: September 30, 2014Assignee: Biological Responsibility, LLCInventor: Gordon Chiu
-
Patent number: 8846741Abstract: The present invention relates to N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives of the formula (I), (II), (III) or (IV) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such N-substituted amino-benzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, and the use of such N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives for therapeutic purposes. The N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives are GlyT1 inhibitors.Type: GrantFiled: November 19, 2012Date of Patent: September 30, 2014Assignees: AbbVie Inc., AbbVie Deutschland GmbH & Co. KGInventors: Wilhelm Amberg, Udo Lange, Frauke Pohlki, Ernesto Santandrea, Charles Hutchins
-
Patent number: 8846742Abstract: The present invention relates to compounds that may be used to inhibit activation of protein kinase G (“PKG”). It is based, at least in part, on the discovery of the tertiary structure of PKG and the identification of molecules that either bind to the active site of PKG and/or are analogs of balanol.Type: GrantFiled: February 14, 2007Date of Patent: September 30, 2014Assignee: The Trustees of Columbia University in the City of New YorkInventors: Richard Ambron, Ying-Ju Sung, Jeremy Greenwood, Leah Frye, Shi-Xian Deng, Yuli Xie, Donald W. Landry
-
Patent number: 8846743Abstract: The present invention relates to aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminoindane derivatives, and the use of such aminoindane derivatives for therapeutic purposes. The aminoindane derivatives are GlyT1 inhibitors.Type: GrantFiled: August 10, 2011Date of Patent: September 30, 2014Assignees: Abbott Laboratories, AbbVie Deutschland GmbH & Co. KGInventors: Frauke Pohlki, Udo Lange, Wilhelm Amberg, Michael Ochse, Berthold Behl, Charles W. Hutchins
-
Patent number: 8846744Abstract: The present invention relates to oral pharmaceutical compositions comprising co-crystals of tramadol and celecoxib and processes for the preparation of these oral pharmaceutical compositions. The present invention also relates to methods of using oral pharmaceutical compositions comprising co-crystals of tramadol and celecoxib as medicaments, more particularly for the treatment of pain.Type: GrantFiled: June 3, 2011Date of Patent: September 30, 2014Assignee: Laboratorios del Dr. Esteve, S.A.Inventors: Luis Soler Ranzani, Albert Falivene Aldea
-
Patent number: 8846745Abstract: A method of treating insulin resistance, obesity and metabolic syndrome by administering an indazolemethoxyalkanoic acid as described herein.Type: GrantFiled: May 8, 2012Date of Patent: September 30, 2014Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.Inventors: Angelo Guglielmotti, Giuseppe Biondi
-
Patent number: 8846746Abstract: The present invention provides a pyrazole compound of the following general Formula [Ib] having SGLT1 inhibitory activity, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and its pharmaceutical use: wherein each symbol is the same as defined in the description.Type: GrantFiled: August 30, 2012Date of Patent: September 30, 2014Assignee: Japan Tobacco Inc.Inventors: Tomoya Miura, Yosuke Ogoshi, Kazuhito Ueyama, Dai Motoda, Toshihiko Iwayama, Koichi Suzawa, Hironobu Nagamori, Hiroshi Ueno, Akihiko Takahashi, Kazuyuki Sugimoto
-
Patent number: 8846747Abstract: Provided are compounds which generally have a triketone structure. Examples of the compounds include derivatives of 1,3-cyclohexanedione, such as: 1,3-cyclohexanedione, 2-propanoyl-5-cyclohexyl-; 1,3-cyclohexanedione, 2-propanoyl-5-[4-fluorophenyl]-; 1,3-cyclohexanedione, 2-acetyl-5-[thien-2-yl]-; 1,3-cyclohexanedione, 2-acetyl-5-butyl-; and 1,3-cyclohexanedione, 2-propanoyl-5-[bicyclo[2.2.1]hept-2-en-5-yl]-. The compounds can be used to alter the lifespan of eukaryotic organisms and treat inflammation.Type: GrantFiled: November 17, 2010Date of Patent: September 30, 2014Assignees: University of Rochester, Southern Research InstituteInventors: David S. Goldfarb, Joseph A. Maddry, Lynn Rasmussen, Ellie Lucille White, Krister Wennerberg